2.47
+0.105(+4.45%)
Currency In USD
| Previous Close | 2.36 |
| Open | 2.34 |
| Day High | 2.47 |
| Day Low | 2.34 |
| 52-Week High | 26.05 |
| 52-Week Low | 2.22 |
| Volume | 26,117 |
| Average Volume | 322,765 |
| Market Cap | 40.06M |
| PE | -0.41 |
| EPS | -6.05 |
| Moving Average 50 Days | 2.54 |
| Moving Average 200 Days | 4.25 |
| Change | 0.11 |
If you invested $1000 in Jasper Therapeutics, Inc. (JSPR) since IPO date, it would be worth $25.1 as of October 30, 2025 at a share price of $2.465. Whereas If you bought $1000 worth of Jasper Therapeutics, Inc. (JSPR) shares 3 years ago, it would be worth $337.67 as of October 30, 2025 at a share price of $2.465.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Jasper Therapeutics Announces Pricing of $30 Million Public Offering of Common Stock, Pre-Funded Warrants and Common Warrants
GlobeNewswire Inc.
Sep 19, 2025 4:07 AM GMT
REDWOOD CITY, Calif., Sept. 19, 2025 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (“Jasper”), a clinical-stage biotechnology company focused on development of briquilimab, a novel antibody therapy targeting KIT (CD117) to address ma
Jasper Therapeutics Announces Proposed Public Offering of Common Stock, Pre-Funded Warrants and Common Warrants
GlobeNewswire Inc.
Sep 18, 2025 8:08 PM GMT
REDWOOD CITY, Calif., Sept. 18, 2025 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (“Jasper”), a clinical-stage biotechnology company focused on development of briquilimab, a novel antibody therapy targeting KIT (CD117) to address ma
Jasper Therapeutics Announces Corporate Reorganization and Other Cost Cutting Measures to Extend Cash Runway
GlobeNewswire Inc.
Jul 09, 2025 12:00 PM GMT
Reducing workforce by approximately 50% to focus on Chronic Urticaria programs and extend cash runway Dr. Edwin Tucker departing as Chief Medical Officer; Dr. Daniel Adelman to serve as Acting Chief Medical Officer REDWOOD CITY, Calif., July 09, 202